Verdence Capital Advisors LLC Boosts Stock Position in Intuitive Surgical, Inc. (NASDAQ:ISRG)

Verdence Capital Advisors LLC increased its position in Intuitive Surgical, Inc. (NASDAQ:ISRG) by 1.9% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,105 shares of the medical equipment provider’s stock after acquiring an additional 40 shares during the quarter. Verdence Capital Advisors LLC’s holdings in Intuitive Surgical were worth $710,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the company. OFI Invest Asset Management bought a new stake in shares of Intuitive Surgical during the 3rd quarter valued at $25,000. Baystate Wealth Management LLC lifted its position in shares of Intuitive Surgical by 150.0% in the fourth quarter. Baystate Wealth Management LLC now owns 75 shares of the medical equipment provider’s stock valued at $25,000 after acquiring an additional 45 shares in the last quarter. Headinvest LLC purchased a new stake in shares of Intuitive Surgical during the third quarter worth about $28,000. Stone House Investment Management LLC boosted its stake in Intuitive Surgical by 100.0% in the 3rd quarter. Stone House Investment Management LLC now owns 100 shares of the medical equipment provider’s stock worth $29,000 after purchasing an additional 50 shares during the period. Finally, Truvestments Capital LLC raised its position in shares of Intuitive Surgical by 137.2% during the third quarter. Truvestments Capital LLC now owns 102 shares of the medical equipment provider’s stock valued at $30,000 after buying an additional 59 shares during the last quarter. Institutional investors own 83.64% of the company’s stock.

Insider Buying and Selling

In other Intuitive Surgical news, EVP Myriam Curet sold 4,318 shares of the firm’s stock in a transaction dated Friday, January 26th. The stock was sold at an average price of $370.15, for a total value of $1,598,307.70. Following the completion of the sale, the executive vice president now owns 189 shares of the company’s stock, valued at $69,958.35. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. In other Intuitive Surgical news, EVP Myriam Curet sold 4,318 shares of the firm’s stock in a transaction on Friday, January 26th. The shares were sold at an average price of $370.15, for a total value of $1,598,307.70. Following the completion of the transaction, the executive vice president now owns 189 shares of the company’s stock, valued at $69,958.35. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, CEO Gary S. Guthart sold 24,325 shares of the business’s stock in a transaction on Monday, January 29th. The shares were sold at an average price of $376.06, for a total transaction of $9,147,659.50. Following the sale, the chief executive officer now directly owns 9,425 shares in the company, valued at $3,544,365.50. The disclosure for this sale can be found here. Insiders have sold a total of 248,418 shares of company stock worth $95,927,097 in the last ninety days. 0.80% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

A number of research firms recently weighed in on ISRG. BTIG Research raised their target price on shares of Intuitive Surgical from $412.00 to $421.00 and gave the company a “buy” rating in a report on Friday. Barclays boosted their price objective on shares of Intuitive Surgical from $385.00 to $430.00 and gave the company an “overweight” rating in a research report on Thursday, January 25th. Truist Financial lifted their price target on shares of Intuitive Surgical from $390.00 to $435.00 and gave the stock a “buy” rating in a research note on Wednesday, January 24th. Jefferies Financial Group increased their price objective on shares of Intuitive Surgical from $365.00 to $375.00 and gave the stock a “hold” rating in a research report on Friday. Finally, Citigroup boosted their target price on Intuitive Surgical from $428.00 to $462.00 and gave the company a “buy” rating in a research report on Wednesday, April 3rd. Five equities research analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company. According to MarketBeat, Intuitive Surgical currently has an average rating of “Moderate Buy” and an average target price of $396.17.

Intuitive Surgical Stock Performance

ISRG stock opened at $366.34 on Monday. Intuitive Surgical, Inc. has a one year low of $254.85 and a one year high of $403.76. The firm has a market cap of $129.85 billion, a price-to-earnings ratio of 66.13, a PEG ratio of 5.69 and a beta of 1.36. The firm has a 50-day simple moving average of $386.84 and a two-hundred day simple moving average of $343.86.

Intuitive Surgical (NASDAQ:ISRG) last posted its earnings results on Thursday, April 18th. The medical equipment provider reported $1.50 EPS for the quarter, beating analysts’ consensus estimates of $1.40 by $0.10. The company had revenue of $1.89 billion during the quarter, compared to analysts’ expectations of $1.87 billion. Intuitive Surgical had a net margin of 27.16% and a return on equity of 12.91%. Intuitive Surgical’s revenue for the quarter was up 11.5% compared to the same quarter last year. During the same quarter in the prior year, the company posted $1.00 earnings per share. As a group, equities analysts predict that Intuitive Surgical, Inc. will post 4.93 earnings per share for the current fiscal year.

Intuitive Surgical Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.